Edition:
United States

Athenex Inc (ATNX.OQ)

ATNX.OQ on NASDAQ Stock Exchange Global Select Market

16.83USD
15 Dec 2017
Change (% chg)

-- (--)
Prev Close
$16.83
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
73,053
52-wk High
$20.43
52-wk Low
$11.25

Latest Key Developments (Source: Significant Developments)

Almirall And Athenex Announces Partnership For Treatment Of Actinic Keratosis
Monday, 11 Dec 2017 11:31am EST 

Dec 11 (Reuters) - Almirall SA ::ALMIRALL AND ATHENEX ANNOUNCE STRATEGIC PARTNERSHIP FOR THE TREATMENT OF ACTINIC KERATOSIS.ALMIRALL SA - CO AND ATHENEX HAVE ENTERED INTO A PARTNERSHIP TO DEVELOP AND COMMERCIALIZE KX2-391 IN UNITED STATES AND EUROPE.ALMIRALL - ATHENEX WILL GRANT EXCLUSIVE LICENSE TO ALMIRALL TO RESEARCH, COMMERCIALIZE KX2-391 IN THE U.S., EUROPEAN COUNTRIES, INCLUDING RUSSIA.ALMIRALL SA - UNDER TERMS OF PARTNERSHIP AGREEMENT, ATHENEX WILL RECEIVE AN UP-FRONT FEE AND NEAR-TERM PAYMENTS OF UP TO $55 MILLION.ALMIRALL SA - ATHENEX WILL BE ELIGIBLE TO RECEIVE LAUNCH AND ADDITIONAL INDICATIONS MILESTONES FOR $65 MILLION.ALMIRALL SA - DEAL INCLUDES SALES PERFORMANCE MILESTONES OF KX2-391 ESTIMATED TO BE $155 MILLION.ALMIRALL - THERE WILL BE TIERED ROYALTIES STARTING AT 15% BASED ON ANNUAL NET SALES, WITH INCREMENTAL INCREASES IN ROYALTY RATES WITH INCREASED SALES.ALMIRALL SA - ATHENEX WILL BE RESPONSIBLE FOR CONDUCTING ALL PRECLINICAL AND CLINICAL STUDIES UP TO U.S. FDA APPROVAL.  Full Article

Athenex Announces Planned Retirement Of Chief Financial Officer Nick Riehle
Friday, 1 Dec 2017 08:00am EST 

Athenex Inc ::ATHENEX ANNOUNCES PLANNED RETIREMENT OF CHIEF FINANCIAL OFFICER NICK RIEHLE.ATHENEX INC - ‍COMPANY WILL COMMENCE AN EXECUTIVE SEARCH TO IDENTIFY A SUITABLE REPLACEMENT FOR CFO ROLE​.ATHENEX INC - ‍RIEHLE WILL CONTINUE TO SERVE AS AN ADVISOR TO COMPANY​.  Full Article

Athenex announces Q3 revenue of $14 million
Thursday, 9 Nov 2017 07:00am EST 

Nov 9 (Reuters) - Athenex Inc :Athenex, Inc. Announces third quarter 2017 results.Q3 revenue rose 149 percent to $14 million.Sees FY 2017 revenue $33 million to $35 million.Says ‍company raises full-year revenue guidance to range of $33 million - $35 million​.FY2017 revenue view $32.3 million -- Thomson Reuters I/B/E/S.Athenex Inc - Sees launch of 4 additional products in Athenex Pharmaceutical division & 2 products in Athenex Pharma solutions in 4Q'17​.  Full Article

Athenex announces positive recommendations from the ‍DSMB to continue the oraxol phase iii program
Thursday, 5 Oct 2017 08:00am EDT 

Oct 5 (Reuters) - Athenex Inc :Athenex announces positive recommendations from the Drug Safety Monitoring Board to continue the oraxol phase iii program.Athenex Inc - ‍DSMB encouraged rapid patient recruitment toward scheduled second interim analysis at 180 patients​.Athenex Inc - ‍DSMB unanimously recommended continuation of oraxol phase iii study​.Athenex Inc - ‍adverse event of painful neuropathy was "uncommon" with oraxol treatment​.Athenex Inc - expect clinical trial to proceed on track with rapid patient recruitment timelines & scheduled second interim analysis at 180 patients in 2018​.Athenex Inc - ‍expect trial to proceed on track with scheduled second interim analysis at 180 patients in 2018​.  Full Article

Athenex Inc announces first patient recruitment in phase III clinical trials for KX-01 ointment
Monday, 25 Sep 2017 08:00am EDT 

Sept 25 (Reuters) - Athenex Inc :Athenex, Inc. announces first patient recruitment in phase III clinical trials for KX-01 ointment for actinic keratosis.Athenex Inc - ‍Expects to complete recruitment of phase III studies within 8 months​.  Full Article

Athenex Inc announces second quarter 2017 results
Monday, 14 Aug 2017 07:00am EDT 

Aug 14 (Reuters) - Athenex Inc :Athenex Inc announces second quarter 2017 results.Q2 revenue $4.6 million versus $5.2 million.Athenex Inc - ‍expect full-year revenues in range of $30 million to $34 million, inclusive of opportunity created by U.S. sodium bicarbonate shortage​.  Full Article

Athenex announces approval of tax incentives from State of New York for Dunkirk facility
Thursday, 27 Jul 2017 08:00am EDT 

July 27 (Reuters) - Athenex Inc :Athenex inc - ‍obtained new york state and local tax incentives related to its pharmaceutical manufacturing facility in town of dunkirk, new york​.Athenex inc - ‍new york state will invest $200 million to construct pharmaceutical manufacturing facility​.  Full Article

Athenex reports commencement of patient enrollment for oraxol-plus-ramucirumab phase 1b clinical trial in gastric cancer
Wednesday, 19 Jul 2017 08:00am EDT 

July 19 (Reuters) - Athenex Inc ::Athenex Inc. announces commencement of patient enrollment for oraxol-plus-ramucirumab phase 1b clinical trial in gastric cancer.  Full Article

Huateng Ma reports 11.6 pct passive stake in Athenex
Thursday, 13 Jul 2017 04:05pm EDT 

July 13 (Reuters) - Athenex Inc :Huateng Ma reports 11.6 percent passive stake in Athenex Inc as of June 14 - SEC filing.  Full Article

Athenex submits IND application of oraxol to Chinese FDA
Wednesday, 5 Jul 2017 07:00am EDT 

July 5 (Reuters) - Athenex Inc :Athenex Inc announces submission of investigational new drug application of oraxol to Chinese FDA.Says application has been accepted by Chinese FDA for review.Athenex Inc - Chinese subsidiary submitted an investigational new drug application to Chinese FDA for oraxol, an oral formulation of paclitaxel.  Full Article

BRIEF-Athenex Inc ‍Initiates Oral Eribulin Investigational New Drug Development Program For Oncology Indications​

* ATHENEX INC - ‍INITIATION OF AN ORAL ERIBULIN INVESTIGATIONAL NEW DRUG DEVELOPMENT PROGRAM FOR ONCOLOGY INDICATIONS​ Source text for Eikon: Further company coverage: